Peter Lawson
Stock Analyst at Barclays
(1.89)
# 2,986
Out of 4,711 analysts
93
Total ratings
35.14%
Success rate
-9.37%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Peter Lawson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMEA Biomea Fusion | Maintains: Equal-Weight | $9 → $11 | $4.23 | +160.05% | 4 | Oct 30, 2024 | |
| RCUS Arcus Biosciences | Maintains: Overweight | $25 → $29 | $15.50 | +87.10% | 6 | Oct 25, 2024 | |
| RVMD Revolution Medicines | Maintains: Overweight | $54 → $60 | $44.06 | +36.18% | 3 | Sep 27, 2024 | |
| RLAY Relay Therapeutics | Maintains: Overweight | $14 → $17 | $4.16 | +308.65% | 5 | Sep 10, 2024 | |
| SNDX Syndax Pharmaceuticals | Maintains: Overweight | $32 → $33 | $13.08 | +152.29% | 4 | Aug 15, 2024 | |
| IMCR Immunocore Holdings | Maintains: Overweight | $92 → $66 | $28.33 | +133.01% | 2 | Aug 9, 2024 | |
| MGNX MacroGenics | Maintains: Overweight | $9 → $8 | $3.18 | +151.57% | 8 | Jul 31, 2024 | |
| ARVN Arvinas | Maintains: Overweight | $60 → $48 | $18.48 | +159.74% | 6 | Jul 31, 2024 | |
| BPMC Blueprint Medicines | Maintains: Equal-Weight | $75 → $105 | $90.14 | +16.49% | 10 | Jul 29, 2024 | |
| NRIX Nurix Therapeutics | Maintains: Overweight | $20 → $31 | $19.83 | +56.33% | 2 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $13 → $17 | $12.49 | +36.11% | 3 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $13 | $3.10 | +319.35% | 1 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $25 | $33.29 | -24.90% | 4 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $9 | $2.97 | +203.03% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $22 | $7.38 | +198.10% | 5 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $47 → $63 | $35.59 | +77.02% | 3 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $10 | $1.68 | +495.24% | 3 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $2 → $1 | $0.60 | +65.32% | 2 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $5 | $1.30 | +284.62% | 4 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $8 | $0.64 | +1,159.84% | 2 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $14.68 | +104.36% | 1 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $3.5 | $1.09 | +221.10% | 4 | Jul 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $355 → $365 | $136.02 | +168.34% | 1 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $46 | $35.42 | +29.87% | 2 | Oct 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underweight | $28 | $24.13 | +16.04% | 1 | Mar 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $0.93 | +3,131.71% | 1 | Mar 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $17 → $45 | $1.31 | +3,335.11% | 2 | Jan 23, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $16 → $45 | $40.72 | +10.51% | 2 | Jan 23, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $1.19 | +5,782.35% | 1 | Jul 14, 2017 |
Biomea Fusion
Oct 30, 2024
Maintains: Equal-Weight
Price Target: $9 → $11
Current: $4.23
Upside: +160.05%
Arcus Biosciences
Oct 25, 2024
Maintains: Overweight
Price Target: $25 → $29
Current: $15.50
Upside: +87.10%
Revolution Medicines
Sep 27, 2024
Maintains: Overweight
Price Target: $54 → $60
Current: $44.06
Upside: +36.18%
Relay Therapeutics
Sep 10, 2024
Maintains: Overweight
Price Target: $14 → $17
Current: $4.16
Upside: +308.65%
Syndax Pharmaceuticals
Aug 15, 2024
Maintains: Overweight
Price Target: $32 → $33
Current: $13.08
Upside: +152.29%
Immunocore Holdings
Aug 9, 2024
Maintains: Overweight
Price Target: $92 → $66
Current: $28.33
Upside: +133.01%
MacroGenics
Jul 31, 2024
Maintains: Overweight
Price Target: $9 → $8
Current: $3.18
Upside: +151.57%
Arvinas
Jul 31, 2024
Maintains: Overweight
Price Target: $60 → $48
Current: $18.48
Upside: +159.74%
Blueprint Medicines
Jul 29, 2024
Maintains: Equal-Weight
Price Target: $75 → $105
Current: $90.14
Upside: +16.49%
Nurix Therapeutics
Jul 15, 2024
Maintains: Overweight
Price Target: $20 → $31
Current: $19.83
Upside: +56.33%
Jun 7, 2024
Maintains: Overweight
Price Target: $13 → $17
Current: $12.49
Upside: +36.11%
May 24, 2024
Maintains: Overweight
Price Target: $18 → $13
Current: $3.10
Upside: +319.35%
Apr 11, 2024
Downgrades: Equal-Weight
Price Target: $25
Current: $33.29
Upside: -24.90%
Mar 7, 2024
Maintains: Overweight
Price Target: $7 → $9
Current: $2.97
Upside: +203.03%
Feb 29, 2024
Maintains: Overweight
Price Target: $18 → $22
Current: $7.38
Upside: +198.10%
Feb 29, 2024
Maintains: Overweight
Price Target: $47 → $63
Current: $35.59
Upside: +77.02%
Feb 27, 2024
Maintains: Overweight
Price Target: $6 → $10
Current: $1.68
Upside: +495.24%
Aug 10, 2023
Maintains: Underweight
Price Target: $2 → $1
Current: $0.60
Upside: +65.32%
Aug 4, 2023
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $1.30
Upside: +284.62%
Aug 5, 2022
Maintains: Overweight
Price Target: $14 → $8
Current: $0.64
Upside: +1,159.84%
Jul 28, 2022
Initiates: Overweight
Price Target: $30
Current: $14.68
Upside: +104.36%
Jul 7, 2022
Maintains: Overweight
Price Target: $7 → $3.5
Current: $1.09
Upside: +221.10%
Aug 6, 2021
Maintains: Underweight
Price Target: $355 → $365
Current: $136.02
Upside: +168.34%
Oct 22, 2020
Upgrades: Overweight
Price Target: $46
Current: $35.42
Upside: +29.87%
Mar 4, 2020
Initiates: Underweight
Price Target: $28
Current: $24.13
Upside: +16.04%
Mar 4, 2020
Initiates: Overweight
Price Target: $30
Current: $0.93
Upside: +3,131.71%
Jan 23, 2018
Upgrades: Buy
Price Target: $17 → $45
Current: $1.31
Upside: +3,335.11%
Jan 23, 2018
Upgrades: Buy
Price Target: $16 → $45
Current: $40.72
Upside: +10.51%
Jul 14, 2017
Initiates: Buy
Price Target: $70
Current: $1.19
Upside: +5,782.35%